Effect of clinical status on survival in patients with borderline or locally advanced pancreatic adenocarcinoma

Effect of clinical status on survival in patients with borderline or locally advanced pancreatic adenocarcinoma

Abstract Objective To determine the effect of clinical status (weight variation and performance status [PS]) at diagnosis and during induction treatment on resectability and overall survival (OS) rates in patients with borderline resectable (BRPC) or locally advanced pancreatic cancer (LAPC). Method...

Full description

Bibliographic Details
Main Authors:	Pauline Duconseil, Jonathan Garnier, Victoria Weets, Jacques Ewald, Ugo Marchese, Marine Gilabert, Laurence Moureau-Zabotto, Flora Poizat, Marc Giovannini, Jean-Robert Delpero, Olivier Turrini
Format:	Article
Language:	English
Published:	BMC 2019-06-01
Series:	World Journal of Surgical Oncology
Online Access:	http://link.springer.com/article/10.1186/s12957-019-1637-1

Similar Items

Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a prospective cohort study
by: Jonathan Garnier, et al.
Published: (2020-03-01)

A pancreatic zone at higher risk of fistula after enucleation
by: Pauline Duconseil, et al.
Published: (2018-08-01)

Prospective Evaluation of Resection Margins Using Standardized Specimen Protocol Analysis among Patients with Distal Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma
by: Jonathan Garnier, et al.
Published: (2021-07-01)

Has the non-resection rate decreased during the last two decades among patients undergoing surgical exploration for pancreatic adenocarcinoma?
by: C. Mattevi, et al.
Published: (2020-08-01)

A single-center experience with pancreatic cystic neuroendocrine tumors
by: Ange Khalil, et al.
Published: (2020-08-01)

Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer
by: Rémy Nicolle, et al.
Published: (2020-07-01)

Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts
by: Rémy Nicolle, et al.
Published: (2017-11-01)

Contemporary Review of Borderline Resectable Pancreatic Ductal Adenocarcinoma
by: Morgan Bonds, et al.
Published: (2019-08-01)

Parenchymal Sparing Resection: Options in Duodenal and Pancreatic Surgery
by: Ugo Marchese, et al.
Published: (2021-04-01)

FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma
by: Changhoon Yoo, et al.
Published: (2020-09-01)

Isolated Splenic Metastases of Her2+++ Gastroesophageal Junction Adenocarcinoma
by: Julie Sigrand, et al.
Published: (2016-03-01)

A 25-gene classifier predicts overall survival in resectable pancreatic cancer
by: David J. Birnbaum, et al.
Published: (2017-09-01)

Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma
by: Katherine V. Trinh, et al.
Published: (2020-09-01)

An excerpt of international consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017
by: QI Bing, et al.
Published: (2018-03-01)

Impact of the Siewert Classification on the Outcome of Patients Treated by Preoperative Chemoradiotherapy for a Nonmetastatic Adenocarcinoma of the Oesophagogastric Junction
by: Laurence Moureau-Zabotto, et al.
Published: (2015-01-01)

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma
by: Hosein Peter J, et al.
Published: (2012-05-01)

Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma
by: Siddharth Iyengar, et al.
Published: (2021-09-01)

Aspiration pneumonia following oncologic digestive surgery: Proposal for a classification
by: Jonathan Garnier, et al.
Published: (2021-06-01)

Extended Venous Resections for Borderline Resectable Pancreatic Head Adenocarcinoma—A Retrospective Studies of Nine Cases
by: Nicolae Bacalbasa, et al.
Published: (2021-07-01)

Utility of CT to Differentiate Pancreatic Parenchymal Metastasis from Pancreatic Ductal Adenocarcinoma
by: Maxime Barat, et al.
Published: (2021-06-01)

Le décryptage omique de l'hétérogénéité de l'adénocarcinome pancréatique : de la paillasse au lit du patient
by: Duconseil, Pauline
Published: (2018)

Borderline-resectable pancreatic adenocarcinoma: Contour irregularity of the venous confluence in pre-operative computed tomography predicts histopathological infiltration.
by: Georgios A Kaissis, et al.
Published: (2019-01-01)

Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data
by: Francesco Giovinazzo, et al.
Published: (2020-08-01)

Computed tomography-guided microwave ablation of perivascular liver metastases from colorectal cancer: a study of the ablation zone, feasibility, and safety
by: Jean Izaaryene, et al.
Published: (2021-01-01)

Solitary Fibrous Tumor in the Round Ligament of the Liver: A Fortunate Intraoperative Discovery
by: Laura Beyer, et al.
Published: (2012-04-01)

Cutting‐edge strategies for borderline resectable pancreatic cancer
by: Rajesh S. Shinde, et al.
Published: (2019-07-01)

Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes
by: Gwen Lomberk, et al.
Published: (2018-05-01)

Survival Analysis in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Chemoradiotherapy Followed by Surgery According to the International Consensus on the 2017 Definition of Borderline Resectable Cancer
by: Aoi Hayasaki, et al.
Published: (2018-03-01)

Optimal Preoperative Multidisciplinary Treatment in Borderline Resectable Pancreatic Cancer
by: Nana Kimura, et al.
Published: (2021-12-01)

Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer
by: Quisette P. Janssen, et al.
Published: (2020-01-01)

Preoperative chemotherapy and carbon ions therapy for treatment of resectable and borderline resectable pancreatic adenocarcinoma: a prospective, phase II, multicentre, single-arm study
by: Viviana Vitolo, et al.
Published: (2019-09-01)

Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma
by: Qiancheng Hu, et al.
Published: (2019-07-01)

Liquid Biopsy Approach for Pancreatic Ductal Adenocarcinoma
by: Etienne Buscail, et al.
Published: (2019-06-01)

Pancreatic Ductal Adenocarcinoma Associated with Autoimmune Pancreatitis
by: Raffaele Pezzilli, et al.
Published: (2011-07-01)

Perioperative Predictors of Early Recurrence for Resectable and Borderline-Resectable Pancreatic Cancer
by: Masafumi Imamura, et al.
Published: (2021-05-01)

Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology.
by: María José Ferri, et al.
Published: (2016-01-01)

Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models
by: Owen Hoare, et al.
Published: (2021-05-01)

Syndecans and Pancreatic Ductal Adenocarcinoma
by: Nausika Betriu, et al.
Published: (2021-02-01)

Omics Approaches in Pancreatic Adenocarcinoma
by: Iranzu González-Borja, et al.
Published: (2019-07-01)

THE SUBTYPES OF PANCREATIC DUCTAL ADENOCARCINOMAS
by: Apeksha Kakkar, et al.
Published: (2016-12-01)